PMID- 23426758
OWN - NLM
STAT- MEDLINE
DCOM- 20140725
LR  - 20130301
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Linking)
VI  - 7
IP  - 4
DP  - 2013 Apr
TI  - The effect of a proton pump inhibitor on bone metabolism in ovariectomized rats.
PG  - 1267-72
LID - 10.3892/mmr.2013.1327 [doi]
AB  - Recent studies revealed that long-term intake of proton pump inhibitor (PPI) 
      increases the risk of vertebral or hip fracture; however, the exact mechanism for 
      this is not known. To evaluate the effect of long-term PPI therapy on bone 
      turnover, we analyzed the signaling pathway involved in osteoclast 
      differentiation and bone resorption/formation markers using ovariectomized rats. 
      Six-week-old Sprague-Dawley (S-D) rats were ovariectomized, and two weeks later 
      they were divided into four groups (group A, normal diet + placebo; group B, low 
      calcium diet + placebo; group C, normal diet + PPI; and group D, low calcium diet 
      + PPI). Omeprazole, at a concentration of 30 mg/kg, was administered orally for 
      eight weeks and the rats were sacrificed when they were 16 weeks old. The 
      relative expression levels of the receptor activator of NF-kappaB ligand 
      (RANKL)/osteoprotegerin (OPG) ratio, c-Fos, nuclear factor of activated T cells 
      c1 (NFATc1) and osteocalcin in femoral bone marrow cells were compared, and serum 
      C-terminal cross-linking telopeptide of type I (CTX-1) levels were determined. 
      The relative ratio of RANKL/OPG was increased in group D, and gene expression 
      levels of c-Fos and NFATc1 were upregulated in groups B and D, which are involved 
      in differentiation and activation of osteoclasts. Furthermore, expression levels 
      of osteocalcin, a bone formation marker, were decreased and levels of serum 
      CTX-1, a bone resorption marker, were increased in group D. Taken together, a low 
      calcium diet and PPI administration are thought to collaborate in order to alter 
      osteoclast activity and bone resorption signaling.
FAU - Joo, Moon Kyung
AU  - Joo MK
AD  - Division of Gastroenterology, Department of Internal Medicine, Korea University 
      College of Medicine, Guro Hospital, Seoul 152-703, Republic of Korea.
FAU - Park, Jong-Jae
AU  - Park JJ
FAU - Lee, Beom Jae
AU  - Lee BJ
FAU - Kim, Ji Hoon
AU  - Kim JH
FAU - Yeon, Jong Eun
AU  - Yeon JE
FAU - Kim, Jae Seon
AU  - Kim JS
FAU - Byun, Kwan Soo
AU  - Byun KS
FAU - Bak, Young-Tae
AU  - Bak YT
LA  - eng
PT  - Journal Article
DEP - 20130219
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Osteoprotegerin)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (RANK Ligand)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Animals
MH  - Bone Resorption/*metabolism/pathology
MH  - Bone and Bones/drug effects/*metabolism
MH  - Calcium/blood
MH  - Cell Differentiation/*drug effects
MH  - Gene Expression Regulation
MH  - Humans
MH  - Osteoclasts/drug effects/metabolism
MH  - Osteoprotegerin/biosynthesis
MH  - Ovariectomy
MH  - Proton Pump Inhibitors/*administration & dosage/adverse effects
MH  - RANK Ligand/biosynthesis
MH  - Rats
MH  - Signal Transduction/drug effects
EDAT- 2013/02/22 06:00
MHDA- 2014/07/26 06:00
CRDT- 2013/02/22 06:00
PHST- 2012/10/30 00:00 [received]
PHST- 2013/02/13 00:00 [accepted]
PHST- 2013/02/22 06:00 [entrez]
PHST- 2013/02/22 06:00 [pubmed]
PHST- 2014/07/26 06:00 [medline]
AID - 10.3892/mmr.2013.1327 [doi]
PST - ppublish
SO  - Mol Med Rep. 2013 Apr;7(4):1267-72. doi: 10.3892/mmr.2013.1327. Epub 2013 Feb 19.